Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ph.1, Open-Label, Dose Escalation & Expansion for Safety, Tolerability, PK, & Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.

Next Previous
Trial Profile

Ph.1, Open-Label, Dose Escalation & Expansion for Safety, Tolerability, PK, & Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STP 707 (Primary)
  • Indications Colon cancer; Colorectal cancer; Liver cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Sirnaomics

Most Recent Events

  • 28 Jun 2024 According to a Sirnaomics media release, the Group has completed a dose escalation study in 11 pancreatic cancer patients, conducted in 11 oncology clinics in the U.S. As per the preliminary results, strong safety profile and stable disease activity has been shown by STP707 for treatment of pancreatic cancer patients.
  • 15 Mar 2024 Number of treatment arms increased from 5 to 6 by the addition of Arm E for 36 mg dose of STP 707. Arm F is allocated to the 48 mg dose.
  • 15 Mar 2024 Planned End Date changed from 1 Sep 2024 to 30 Mar 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top